Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

L Kappos, A Bar-Or, BAC Cree, RJ Fox, G Giovannoni… - The Lancet, 2018 - thelancet.com
Background No treatment has consistently shown efficacy in slowing disability progression
in patients with secondary progressive multiple sclerosis (SPMS). We assessed the effect of …

The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease

M Kremenchutzky, GPA Rice, J Baskerville… - Brain, 2006 - academic.oup.com
… corticospinal tract dysfunction in progressive disease and the … Despite considerable individual
variation, the progressive … to all forms of progressive multiple sclerosis. The possibility that …

Multiple sclerosis and progressive resistance training: a systematic review

T Kjølhede, K Vissing, U Dalgas - Multiple Sclerosis Journal, 2012 - journals.sagepub.com
… Recently progressive resistance training (PRT) has been recognised as an effective tool
in the rehabilitation of persons with multiple sclerosis (MS). The objective of this study was to …

Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis

Y Ge, RI Grossman, JK Udupa, L Wei, LJ Mannon… - Radiology, 2000 - pubs.rsna.org
… -remitting and secondary progressive multiple sclerosis (MS) … -remitting, nine secondary
progressive) and in 20 control … year in those with secondary progressive MS. There was a …

Siponimod for the treatment of secondary progressive multiple sclerosis

L Dumitrescu, CS Constantinescu… - Expert Opinion on …, 2019 - Taylor & Francis
… of progressive MS remains an unmet need. … progressive MS. The authors reviewed PubMed
English literature using the keywords ‘siponimod’ or ‘BAF312’ and ‘multiple sclerosis.’ They …

Memory disturbance in chronic progressive multiple sclerosis

SM Rao, TA Hammeke, MP McQuillen… - Archives of …, 1984 - jamanetwork.com
• Forty-four patients with chronic progressive multiple sclerosis (MS) were compared with
age- and education-matched control groups on a battery of clinical and experimental memory …

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

HP Hartung, R Gonsette, N Konig, H Kwiecinski… - The Lancet, 2002 - thelancet.com
… Treatment options for patients with secondary progressive multiple sclerosis are few.
Encouraging results in open-label studies prompted this randomised trial of mitoxantrone in such …

Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis

SR Choi, OW Howell, D Carassiti, R Magliozzi… - Brain, 2012 - academic.oup.com
… of the potential mechanisms of the CNS injury that underlies the gradual progression of
clinical disability in both secondary progressive and primary progressive multiple sclerosis. …

A longitudinal study of cognition in primary progressive multiple sclerosis

SJ Camp, VL Stevenson, AJ Thompson, GT Ingle… - Brain, 2005 - academic.oup.com
multiple sclerosis, and the results of these studies remain inconclusive. No serial
neuropsychological data of an exclusively primary progressive … primary progressive multiple

Prevalence of fatigue and its association with clinical features in progressive and non-progressive forms of Multiple Sclerosis

S Rooney, L Wood, F Moffat, L Paul - Multiple sclerosis and related …, 2019 - Elsevier
… Fatigue is a complex and disabling symptom of Multiple Sclerosis (MS); however, there is …
Furthermore, few studies have considered these relationships specifically in a progressive